{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1382262946354224641.json","@type":"Researcher","foaf:Person":[{"foaf:name":[{"@value":"Paul A. Marks"}],"foaf:familyName":[{"@value":"Marks"}],"foaf:givenName":[{"@value":"Paul A."}]}],"product":[{"@id":"https://cir.nii.ac.jp/crid/1362262946354224640","@type":"Article","productIdentifier":[{"@type":"DOI","@value":"10.4161/cc.4.4.1564"},{"@type":"URI","@value":"https://www.tandfonline.com/doi/pdf/10.4161/cc.4.4.1564"}],"notation":[{"@value":"Histone Deacetylase Inhibitors in Programmed Cell Death and Cancer Therapy"}],"relation":[{"type":"creator"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.4161/cc.4.4.1564_ZRJT0JVCZTWscmrXA4dXGnQsFzc"}]}